Anthony Paronneau - McDermott Will & Emery

Overview


Anthony Paronneau advises clients on all aspects of corporate and business law, with a particular focus on pharmaceutical, medical device, biotech and healthcare industries.

Show More

Results


  • Represented Vivet Therapeutics, a French biotech, on its exclusive option to be acquired by and its sale of a 15% ownership stake to Pfizer.
  • Represented Servier on its acquisition of Symphogen.
  • Represented Arterial Remodeling Technologies (ART), a French medtech developing an active bioabsorbable stent for the treatment of coronary disease, on its structured sale to the Japanese group Terumo Corporation.

Show More

Recognitions


  • The Best Lawyers in France, Biotechnology & Life Sciences, 2024
  • Chambers Europe, France: Pharma/Life Sciences: Corporate, Up and Coming, 2022-2023
  • The Legal 500 EMEA, Leading Individual in France: Healthcare & Life Sciences, 2022 -2023
  • IFLR1000, Corporate and M&A, 2022-2023
  • Décideurs Juridiques, Capital Investments: Operational Risk, Excellent, 2020
  • Décideurs Juridiques, Health, Pharma and Biotechnology: Digital Health, Forte Notoriété, 2019
  • Décideurs Juridiques, Health, Pharma and Biotechnology: Regulatory, Excellent, 2019

Show More

Credentials


Education
HEC Paris School of Management, Graduate
Université Paris – Sud 11, DEA, Private Law, 2003
Université Paris – Sud 11, Maîtrise, Business Law, 2001

Admissions
Paris

Show More